Literature DB >> 17299097

Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.

William G Wierda1, Susan O'Brien, Xuemei Wang, Stefan Faderl, Alessandra Ferrajoli, Kim-Anh Do, Jorge Cortes, Deborah Thomas, Guillermo Garcia-Manero, Charles Koller, Miloslav Beran, Francis Giles, Farhad Ravandi, Susan Lerner, Hagop Kantarjian, Michael Keating.   

Abstract

The clinical course for patients with chronic lymphocytic leukemia is extremely heterogeneous. The Rai and Binet staging systems have been used to risk-stratify patients; most patients present with early-stage disease. We evaluated a group of previously untreated patients with chronic lymphocytic leukemia (CLL) at initial presentation to University of Texas M. D. Anderson Cancer Center to identify independent characteristics that predict for overall survival. Clinical and routine laboratory characteristics for 1674 previously untreated patients who presented for evaluation of CLL from 1981 to 2004 were included. Univariate and multivariate analyses identified several patient characteristics at presentation that predicted for overall survival in previously untreated patients with CLL. A multivariate Cox proportional hazards model was developed, including the following independent characteristics: age, beta-2 microglobulin, absolute lymphocyte count, sex, Rai stage, and number of involved lymph node groups. Inclusion of patients from a single institution and the proportion of patients younger than 65 years may limit this model. A weighted prognostic model, or nomogram, predictive for overall survival was constructed using these 6 characteristics for 5- and 10-year survival probability and estimated median survival time. This prognostic model may help patients and clinicians in clinical decision making as well as in clinical research and clinical trial design.

Entities:  

Mesh:

Year:  2007        PMID: 17299097     DOI: 10.1182/blood-2005-12-051458

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  114 in total

1.  Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.

Authors:  Davide Rossi; Silvia Rasi; Giulia Fabbri; Valeria Spina; Marco Fangazio; Francesco Forconi; Roberto Marasca; Luca Laurenti; Alessio Bruscaggin; Michaela Cerri; Sara Monti; Stefania Cresta; Rosella Famà; Lorenzo De Paoli; Pietro Bulian; Valter Gattei; Anna Guarini; Silvia Deaglio; Daniela Capello; Raul Rabadan; Laura Pasqualucci; Riccardo Dalla-Favera; Robin Foà; Gianluca Gaidano
Journal:  Blood       Date:  2011-11-10       Impact factor: 22.113

2.  White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia.

Authors:  Ilaria Del Giudice; Francesca Romana Mauro; Maria Stefania De Propris; Simona Santangelo; Marilisa Marinelli; Nadia Peragine; Valeria Di Maio; Mauro Nanni; Rita Barzotti; Francesca Mancini; Daniele Armiento; Francesca Paoloni; Anna Guarini; Robin Foà
Journal:  Haematologica       Date:  2010-12-29       Impact factor: 9.941

3.  A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients.

Authors:  M Gentile; T D Shanafelt; G Cutrona; S Molica; G Tripepi; I Alvarez; F R Mauro; N Di Renzo; F Di Raimondo; I Vincelli; K Todoerti; S Matis; C Musolino; S Fabris; E Vigna; L Levato; S Zupo; F Angrilli; U Consoli; G Festini; G Longo; A Cortelezzi; A Arcari; M Federico; D Mannina; A G Recchia; A Neri; N E Kay; M Ferrarini; F Morabito
Journal:  Leukemia       Date:  2015-12-09       Impact factor: 11.528

Review 4.  The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.

Authors:  Adrian Wiestner
Journal:  Haematologica       Date:  2015-12       Impact factor: 9.941

5.  Predictive value of beta2-microglobulin (beta2-m) levels in chronic lymphocytic leukemia since Binet A stages.

Authors:  Massimo Gentile; Giovanna Cutrona; Antonino Neri; Stefano Molica; Manlio Ferrarini; Fortunato Morabito
Journal:  Haematologica       Date:  2009-06       Impact factor: 9.941

6.  Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.

Authors:  Jacob D Soumerai; Ai Ni; Guan Xing; Julie Huang; Richard R Furman; Jeffrey Jones; Jeffrey P Sharman; Michael Hallek; Adeboye H Adewoye; Ronald Dubowy; Lyndah Dreiling; Andrew D Zelenetz
Journal:  Leuk Lymphoma       Date:  2018-11-08

Review 7.  Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.

Authors:  Hagop Kantarjian; Susan O'Brien; Jorge Cortes; William Wierda; Stefan Faderl; Guillermo Garcia-Manero; Jean-Pierre Issa; Elihu Estey; Michael Keating; Emil J Freireich
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

8.  Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

Authors:  Constantine S Tam; Susan O'Brien; William Wierda; Hagop Kantarjian; Sijin Wen; Kim-Anh Do; Deborah A Thomas; Jorge Cortes; Susan Lerner; Michael J Keating
Journal:  Blood       Date:  2008-04-14       Impact factor: 22.113

9.  Multiple-dose granulocyte-macrophage-colony-stimulating factor plus 23-valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia: a prospective, randomized trial of safety and immunogenicity.

Authors:  Amar Safdar; Gilhen H Rodriguez; Adriana M Rueda; William G Wierda; Alessandra Ferrajoli; Daniel M Musher; Susan O'Brien; Charles A Koller; Gerald P Bodey; Michael J Keating
Journal:  Cancer       Date:  2008-07-15       Impact factor: 6.860

10.  Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.

Authors:  Panagiotis Baliakas; Sabine Jeromin; Michalis Iskas; Anna Puiggros; Karla Plevova; Florence Nguyen-Khac; Zadie Davis; Gian Matteo Rigolin; Andrea Visentin; Aliki Xochelli; Julio Delgado; Fanny Baran-Marszak; Evangelia Stalika; Pau Abrisqueta; Kristina Durechova; George Papaioannou; Virginie Eclache; Maria Dimou; Theodoros Iliakis; Rosa Collado; Michael Doubek; M Jose Calasanz; Neus Ruiz-Xiville; Carolina Moreno; Marie Jarosova; Alexander C Leeksma; Panayiotis Panayiotidis; Helena Podgornik; Florence Cymbalista; Achilles Anagnostopoulos; Livio Trentin; Niki Stavroyianni; Fred Davi; Paolo Ghia; Arnon P Kater; Antonio Cuneo; Sarka Pospisilova; Blanca Espinet; Anastasia Athanasiadou; David Oscier; Claudia Haferlach; Kostas Stamatopoulos
Journal:  Blood       Date:  2019-01-02       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.